Antipsychotic efficacy: Relationship to optimal D2-receptor occupancy
- 1 July 2007
- journal article
- review article
- Published by Cambridge University Press (CUP) in European Psychiatry
- Vol. 22 (5), 267-275
- https://doi.org/10.1016/j.eurpsy.2007.02.005
Abstract
Clinically important differences exist between antipsychotic agents and formulations in terms of safety and tolerability. Features of the biochemical interaction between the antipsychotic and the D2-receptor may underlie these differences. This article reviews current information on the relationship between antipsychotic receptor occupancy and clinical response. A literature search was performed using the keywords ‘antipsychotic or neuroleptic’, ‘receptor’ and ‘occupancy’ and ‘dopamine’ and ‘D2’ supplemented by the authors’ knowledge of the literature. Imaging and clinical data have generally supported the hypotheses that optimal D2-receptor occupancy in the striatum lies in a ‘therapeutic window’ between ∼65 and ∼80%, however, pharmacokinetic and pharmacodynamic properties of a drug should also be taken into account to fully evaluate its therapeutic effects. Additional research, perhaps in preclinical models, is needed to establish D2-receptor occupancy in various regions of the brain and the optimal duration of D2-receptor blockade in order to maximise efficacy and tolerability profiles of atypical antipsychotics and thereby improve treatment outcomes for patients with schizophrenia.Keywords
This publication has 67 references indexed in Scilit:
- Health resource utilization associated with switching to risperidone long‐acting injectionActa Psychiatrica Scandinavica, 2006
- Sustained improvement of clinical outcome with risperidone long-acting injectable in psychotic patients previously treated with olanzapineJournal of Psychopharmacology, 2005
- An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: Results from a long-term studySchizophrenia Research, 2005
- Remission in schizophrenia: Results from a 1-year study of long-acting risperidone injectionSchizophrenia Research, 2005
- Cost-Effectiveness Model Of Long-Acting Risperidone in Schizophrenia in the USPharmacoEconomics, 2005
- Extrapyramidal Symptoms with Atypical AntipsychoticsDrug Safety, 2005
- A meta-analysis of the efficacy of second-generation antipsychoticsSchizophrenia Research, 2003
- Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta™) in patients with schizophreniaInternational Journal of Neuropsychopharmacology, 1999
- D2-Dopamine Receptor Occupancy measured by IBZM-SPECT in Relation to Extrapyramidal Side EffectsPharmacopsychiatry, 1998
- Depot Antipsychotic DrugsDrugs, 1994